186 related articles for article (PubMed ID: 37338806)
1. Direct In Vivo Activation of T Cells with Nanosized Immunofilaments Inhibits Tumor Growth and Metastasis.
Weiss L; Weiden J; Dölen Y; Grad EM; van Dinther EAW; Schluck M; Eggermont LJ; van Mierlo G; Gileadi U; Bartoló-Ibars A; Raavé R; Gorris MAJ; Maassen L; Verrijp K; Valente M; Deplancke B; Verdoes M; Benitez-Ribas D; Heskamp S; van Spriel AB; Figdor CG; Hammink R
ACS Nano; 2023 Jul; 17(13):12101-12117. PubMed ID: 37338806
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.
Rhodes KR; Isser A; Hickey JW; Ben-Akiva E; Meyer RA; Kosmides AK; Livingston NK; Tzeng SY; Schneck JP; Green JJ
ACS Appl Mater Interfaces; 2021 Feb; 13(7):7913-7923. PubMed ID: 33573372
[TBL] [Abstract][Full Text] [Related]
3. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses.
Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C
Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669
[TBL] [Abstract][Full Text] [Related]
4. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
5. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
Hamieh M; Chatillon JF; Dupel E; Bayeux F; Fauquembergue E; Maby P; Drouet A; Duval-Modeste AB; Adriouch S; Boyer O; Latouche JB
Front Immunol; 2021; 12():674276. PubMed ID: 34566953
[TBL] [Abstract][Full Text] [Related]
6. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-based modulation of CD4
Isser A; Silver AB; Pruitt HC; Mass M; Elias EH; Aihara G; Kang SS; Bachmann N; Chen YY; Leonard EK; Bieler JG; Chaisawangwong W; Choy J; Shannon SR; Gerecht S; Weber JS; Spangler JB; Schneck JP
Nat Commun; 2022 Oct; 13(1):6086. PubMed ID: 36241639
[TBL] [Abstract][Full Text] [Related]
8. Biomimetic dendritic polymeric microspheres induce enhanced T cell activation and expansion for adoptive tumor immunotherapy.
Yang H; Sun L; Chen R; Xiong Z; Yu W; Liu Z; Chen H
Biomaterials; 2023 May; 296():122048. PubMed ID: 36842237
[TBL] [Abstract][Full Text] [Related]
9. Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells.
Shrestha B; Zhang Y; Yu B; Li G; Boucher JC; Beatty NJ; Tsai HC; Wang X; Mishra A; Sweet K; Lancet JE; Kelley L; Davila ML
J Immunother; 2020 Apr; 43(3):79-88. PubMed ID: 31834208
[TBL] [Abstract][Full Text] [Related]
10. An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in
Zhang L; Song S; Jin X; Wan X; Shahzad KA; Pei W; Zhao C; Shen C
Cancer Immunol Res; 2019 Jul; 7(7):1188-1201. PubMed ID: 31113806
[TBL] [Abstract][Full Text] [Related]
11. DNA Engineered Lymphocyte-Based Homologous Targeting Artificial Antigen-Presenting Cells for Personalized Cancer Immunotherapy.
Sun L; Shen F; Xiong Z; Yang H; Dong Z; Xiang J; Gu Q; Ji Q; Fan C; Liu Z
J Am Chem Soc; 2022 May; 144(17):7634-7645. PubMed ID: 35438987
[TBL] [Abstract][Full Text] [Related]
12. Facile Transformation of Murine and Human Primary Dendritic Cells into Robust and Modular Artificial Antigen-Presenting Systems by Intracellular Hydrogelation.
Lin JC; Hsu CY; Chen JY; Fang ZS; Chen HW; Yao BY; Shiau GHM; Tsai JS; Gu M; Jung M; Lee TY; Hu CJ
Adv Mater; 2021 Jul; 33(30):e2101190. PubMed ID: 34096117
[TBL] [Abstract][Full Text] [Related]
13. Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy.
Jazirehi AR
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769156
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.
Oelke M; Maus MV; Didiano D; June CH; Mackensen A; Schneck JP
Nat Med; 2003 May; 9(5):619-24. PubMed ID: 12704385
[TBL] [Abstract][Full Text] [Related]
15. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.
Schultze JL; Michalak S; Seamon MJ; Dranoff G; Jung K; Daley J; Delgado JC; Gribben JG; Nadler LM
J Clin Invest; 1997 Dec; 100(11):2757-65. PubMed ID: 9389740
[TBL] [Abstract][Full Text] [Related]
16. [Construction of specific artificial antigen-presenting cells for in vitro activation of CD19 chimeric antigen receptor T cells].
Peng YJ; Wu QY; Liu HY; Zhao J; Wei HF
Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):581-587. PubMed ID: 28539278
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Tumor Metastasis by Artificial Antigen-Presenting Cells via Targeted Microenvironment Regulation and T-Cell Activation.
Lu Y; Li L; Du J; Chen J; Xu X; Yang X; Ding C; Mao C
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55890-55901. PubMed ID: 34787393
[TBL] [Abstract][Full Text] [Related]
18. Nanoscale artificial antigen presenting cells for T cell immunotherapy.
Perica K; De León Medero A; Durai M; Chiu YL; Bieler JG; Sibener L; Niemöller M; Assenmacher M; Richter A; Edidin M; Oelke M; Schneck J
Nanomedicine; 2014 Jan; 10(1):119-29. PubMed ID: 23891987
[TBL] [Abstract][Full Text] [Related]
19. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).
Durai M; Krueger C; Ye Z; Cheng L; Mackensen A; Oelke M; Schneck JP
Cancer Immunol Immunother; 2009 Feb; 58(2):209-20. PubMed ID: 18563409
[TBL] [Abstract][Full Text] [Related]
20. Expansion of melanoma-specific T cells from lymph nodes of patients in stage III: implications for adoptive immunotherapy in treating cancer.
Visioni A; Zhang M; Graor H; Kim J
Surgery; 2012 Oct; 152(4):557-65; discussion 565-6. PubMed ID: 22925133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
